Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Abstract:

:Flecainide is a Class I antiarrhythmic drug of the local anaesthetic type. It can be given either intravenously or orally and its pharmacokinetic properties allow relatively long (12 hours) dosing intervals with oral administration. In several open and a few controlled therapeutic trials, orally administered flecainide has brought about a greater than 90% suppression of ventricular ectopic beats in about 80% of patients. A similar percentage of patients (83%) experienced at least an 80% suppression of their ventricular tachycardia in these trials. A slightly greater response rate was reported with intravenous infusion of flecainide. Initial results in arrhythmias complicating the Wolff-Parkinson-White syndrome have been favourable. Comparative trials are few in number but flecainide has proved to be more effective than quinidine, and possibly more effective than disopyramide, mexiletine, tocainide and propafenone, in suppressing ventricular ectopic activity. The most commonly reported extracardiac adverse effects have been dizziness and visual disturbances. Proarrhythmic effects have been reported in 7 to 8% of patients, with a higher incidence in patients with serious ventricular tachycardia and reduced myocardial function. The moderate negative inotropic effects of flecainide can become clinically significant in patients with impaired ventricular function. Thus flecainide, with its convenient dose schedule and apparently low incidence of serious side effects, would appear to be a useful addition to the antiarrhythmic agents available. Further studies are needed though, to confirm its long term tolerability when used prophylactically.

journal_name

Drugs

journal_title

Drugs

authors

Holmes B,Heel RC

doi

10.2165/00003495-198529010-00001

subject

Has Abstract

pub_date

1985-01-01 00:00:00

pages

1-33

issue

1

eissn

0012-6667

issn

1179-1950

journal_volume

29

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Potential immunological action of purine nucleoside analogues.

    abstract::Purine nucleoside analogues are a new class of drugs with activity against nondividing lymphocytes; thus, they should play a major role in the treatment of low grade lymphoid malignancies. As these drugs are active against resting lymphocytes, harmful effects related to this action were expected and have been reported...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199400476-00009

    authors: Dighiero G

    更新日期:1994-01-01 00:00:00

  • Treatment of the chronic fatigue syndrome. A review and practical guide.

    abstract::The chronic fatigue syndrome (CFS) was formally defined in 1988 to describe a syndrome of severe and disabling fatigue of uncertain aetiology associated with a variable number of somatic and/or psychological symptoms. CFS has been reported in most industrialised countries and is most prevalent in women aged between 20...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199346040-00005

    authors: Blondel-Hill E,Shafran SD

    更新日期:1993-10-01 00:00:00

  • Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.

    abstract::The article Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension, written by Sheridan Hoy, was originally published Online First without open access. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-018-0925-3

    authors: Hoy SM

    更新日期:2018-06-01 00:00:00

  • Clinical evidence with montelukast in the management of chronic childhood asthma.

    abstract:OBJECTIVE:The aim of this article is to review data on the efficacy and safety of montelukast in the treatment of children with asthma. METHODOLOGY:Available published literature, including published abstracts, is reviewed. RESULTS:In patients aged 6 to 14 years with asthma (n = 27), montelukast 5mg demonstrated a si...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200059001-00005

    authors: Becker A

    更新日期:2000-01-01 00:00:00

  • Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.

    abstract::86 patients with a first myocardial infarction presenting within 6 hours of the onset of symptoms were randomly allocated to treatment with intravenous streptokinase or anisoylated plasminogen streptokinase activator complex (APSAC). Plasma concentrations of fibrinogen, plasminogen, alpha 2-antiplasmin and fibrinogen ...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198700333-00046

    authors: Monassier JP,Hanssen M

    更新日期:1987-01-01 00:00:00

  • Drug-resistant tuberculosis: what are the treatment options?

    abstract::Drug-resistant tuberculosis (DR-TB) is an emerging global health threat as treatment involves complex multiple drug regimens, which are longer and more toxic than standard therapy and yet have worse outcomes. In the presence of resistance to one or more first-line drugs, an alternative regimen should be designed. A ma...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11585440-000000000-00000

    authors: Albanna AS,Menzies D

    更新日期:2011-05-07 00:00:00

  • Prospects for the development of new treatments with a rapid onset of action in affective disorders.

    abstract::Several compounds have been claimed to have a faster onset of antidepressant action. However, these trials suffered from lack of appropriate definitions and of standardised and comparable methodology, as far as measurement instruments, dosage strategies and statistical analyses were concerned. This article was underta...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199652040-00001

    authors: Soares JC,Gershon S

    更新日期:1996-10-01 00:00:00

  • Guide to the use of proton pump inhibitors in adult patients.

    abstract::Proton Pump Inhibitors (PPIs) are widely used in the treatment of acid-peptic diseases. Their mechanism of action involves inhibition of the H-K-adenosine triphosphatase enzyme present in the parietal cells of the gastric mucosa. Because PPIs are the most potent inhibitors of gastric acid secretion available, they eff...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868070-00004

    authors: Boparai V,Rajagopalan J,Triadafilopoulos G

    更新日期:2008-01-01 00:00:00

  • Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease.

    abstract::Budesonide is a glucocorticoid with high topical activity, but low systemic bio-availability which results in reduced systemic effects in comparison with other glucocorticoids. To date, it has been evaluated for use in patients with inflammatory bowel disease when administered either orally as a controlled ileal relea...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199550050-00006

    authors: Spencer CM,McTavish D

    更新日期:1995-11-01 00:00:00

  • Hypopigmentary skin disorders: current treatment options and future directions.

    abstract::Alterations of skin and hair pigmentation are important features that have warranted treatment from ancient history on up to modern time. In some cultures, even today patients with vitiligo are regarded as social outcasts and are affected considerably both emotionally and physically. This article presents current opti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464010-00006

    authors: Hartmann A,Bröcker EB,Becker JC

    更新日期:2004-01-01 00:00:00

  • The use of fluoroquinolones in sexually transmitted diseases in Southeast Asia.

    abstract::This paper reviews the use of the fluoroquinolone antibiotics in the management of sexually transmitted diseases (STD) in Southeast Asia. Numerous clinical trials performed in the region have shown that the quinolones are highly effective for treating uncomplicated gonorrhoea. Norfloxacin 800 mg, ofloxacin 400 mg, cip...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199500492-00019

    authors: Sivayathorn A

    更新日期:1995-01-01 00:00:00

  • Phentermine and topiramate extended release (Qsymia™): first global approval.

    abstract::Vivus' proprietary oral capsule containing phentermine and extended-release (ER) topiramate has been approved in the US for the treatment of obesity. Phentermine is an appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily formulation, known as Qsymia™, is designed to produce weight los...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/11640860-000000000-00000

    authors: Cameron F,Whiteside G,McKeage K

    更新日期:2012-10-22 00:00:00

  • The pharmacodynamics and pharmacokinetics of multiple doses of the new H2-receptor antagonist, roxatidine acetate, in healthy men.

    abstract::Roxatidine acetate (HOE 760, TZU 0460) is a new H2-receptor antagonist which is more potent than cimetidine and ranitidine. A randomised, double-blind, placebo-controlled study was conducted in healthy men to determine the effects of multiple oral doses of roxatidine acetate on unstimulated gastric acid secretion, and...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198800353-00011

    authors: Lassman HB,Ho I,Puri SK,Sabo R,Scheffler MR

    更新日期:1988-01-01 00:00:00

  • [Evaluation of the impact of peripheral obliterative arteriopathy on quality of life].

    abstract::Peripheral arterial occlusive disease is a common condition with possible serious consequences. It is usually diagnosed at the intermittent claudication stage. There are 2 objectives of treatment: to prevent ischaemic attacks and to improve quality of life. Treatment efficacy is, however, usually evaluated only in ter...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856003-00004

    authors: Marquis P

    更新日期:1998-01-01 00:00:00

  • The role of the angiotensin system in cardiac glucose homeostasis: therapeutic implications.

    abstract::Resistance to the metabolic actions of insulin is thought to play a determining role in the aetiology of a great variety of disorders, including essential hypertension, accelerated atherosclerosis and cardiomyopathies. ACE inhibitors are recognised as being highly effective therapy for hypertension and cardiac insuffi...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262090-00002

    authors: Bernobich E,de Angelis L,Lerin C,Bellini G

    更新日期:2002-01-01 00:00:00

  • Tocilizumab: a review of its use in the management of rheumatoid arthritis.

    abstract::Tocilizumab (RoActemra or Actemra) is a recombinant humanized monoclonal antibody that acts as an interleukin (IL)-6 receptor antagonist. Intravenous tocilizumab 8 mg/kg (and no less than 4.8 mg), in combination with methotrexate, is approved in the EU for the treatment of moderate to severe active rheumatoid arthriti...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969050-00007

    authors: Oldfield V,Dhillon S,Plosker GL

    更新日期:2009-01-01 00:00:00

  • The cost of treating systemic fungal infections.

    abstract::The increasing incidence of systemic fungal infections and rising medical costs have highlighted the need for an economic appraisal of antifungal agents to determine the most cost-effective therapeutic option. Cost savings derived from the prophylactic or empirical use of antifungal agents have been difficult to estim...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200161001-00005

    authors: van Gool R

    更新日期:2001-01-01 00:00:00

  • Idiopathic membranous nephropathy: management strategies.

    abstract::Treatment of idiopathic membranous nephropathy is based on a 'symptomatic' therapy that includes ACE inhibitors or angiotensin II receptor antagonists, and on an 'aetiological' therapy aimed at modulating underlying immunological mechanisms. The role of the latter is still debated given the usually indolent course of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200969100-00002

    authors: Quaglia M,Stratta P

    更新日期:2009-07-09 00:00:00

  • Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.

    abstract::Pegaspargase (Oncaspar®), a pegylated form of native Escherichia coli-derived L-asparaginase (hereafter referred as E. coliL-asparaginase), is indicated in the USA and EU for the treatment of acute lymphoblastic leukaemia (ALL) as a component of multi-agent chemotherapy in paediatric and adult patients. Relative to E....

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01120-1

    authors: Heo YA,Syed YY,Keam SJ

    更新日期:2019-05-01 00:00:00

  • Liposomal drug formulations. Rationale for development and what we can expect for the future.

    abstract::Liposomes are versatile drug carriers which can be used to solve problems of drug solubility, instability and rapid degradation. Both hydrophilic and hydrophobic drugs can be associated with liposomes and special techniques have been developed for the efficient loading of weak acids and weak bases into liposomes. Lipo...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856050-00001

    authors: Allen TM

    更新日期:1998-11-01 00:00:00

  • Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon.

    abstract:INTRODUCTION:Several pharmacological treatments aiming at a better symptomatic control of osteoarthritis (OA) are used in daily practice but their efficacy is often disputed. The purpose of this network meta-analysis (NMA) is to assess the efficacy on pain and function of the drugs that are most widely prescribed again...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01423-8

    authors: Beaudart C,Lengelé L,Leclercq V,Geerinck A,Sanchez-Rodriguez D,Bruyère O,Reginster JY

    更新日期:2020-12-01 00:00:00

  • Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder.

    abstract::Aripiprazole (Abilify®) is an atypical antipsychotic indicated for the treatment of mania associated with bipolar I disorder. It is unique in its class, as it is a partial agonist of dopamine D(2) and D(3), and serotonin 5-HT(1A) receptors and a modest antagonist of 5-HT(2A) receptors. This article reviews the pharmac...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11208320-000000000-00000

    authors: Dhillon S

    更新日期:2012-01-01 00:00:00

  • Role of cephalosporins in gonorrhoea and other sexually transmitted diseases.

    abstract::Cephalosporins have a role in the treatment of gonorrhoea, and especially infections caused by strains that are penicillin-resistant, either because they produce plasmid-mediated beta-lactamase or they have chromosomally mediated diminished permeability or modified penicillin-binding proteins. Although none of the ora...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198700342-00013

    authors: Phillips I

    更新日期:1987-01-01 00:00:00

  • Pharmacological interventions for the induction of ovulation.

    abstract::Ovulation induction is the most common medical intervention for the treatment of infertility. Clomifene is generally the first treatment choice for patients with amenorrhoea, unless there is profound hypothalamic deficiency. When clomifene fails to induce ovulation, menotropins (human menopausal gonadotrophin) or gona...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199550030-00006

    authors: Collins JA,Hughes EG

    更新日期:1995-09-01 00:00:00

  • Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson's Disease.

    abstract::An enteral suspension (ES)/intestinal gel formulation of levodopa/carbidopa (hereafter referred to as levodopa/carbidopa ES) [Duodopa® (EU); Duopa™ (USA)] has been developed to overcome the fluctuating plasma levodopa concentrations associated with oral levodopa/carbidopa formulations. In various countries, including ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01201-1

    authors: Hoy SM

    更新日期:2019-10-01 00:00:00

  • An overview of the long-term safety experience of nabumetone.

    abstract::Safety data have been gathered in US clinical trials of nabumetone on 1912 patients from August 1981 to May 1988. Dosing in the double-blind trials was 100 mg at bedtime, but in open-label trials patients could increase the dosage of nabumetone to 1500 or 2000 mg if required. Adverse experiences reported in the double...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章

    doi:10.2165/00003495-199000405-00008

    authors: Willkens RF

    更新日期:1990-01-01 00:00:00

  • Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO].

    abstract::The Japanese encephalitis vaccine IC-51 (IXIARO) is an inactivated virus (strain SA(14)-14-2) that is manufactured in cultured Vero cells and is currently being developed for preventive vaccination against the Japanese encephalitis virus. black triangle Administration of IXIARO as a two-dose treatment in healthy adult...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-200969010-00008

    authors: Duggan ST,Plosker GL

    更新日期:2009-01-01 00:00:00

  • Cenobamate: First Approval.

    abstract::Cenobamate (XCOPRI®) is an oral, small molecule neurotherapeutic azole compound that is being developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy. Based on results of two pivotal phase 2 trials, cenobamate was recently approved in the USA for use in the treatment of partial-onset s...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01250-6

    authors: Keam SJ

    更新日期:2020-01-01 00:00:00

  • Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.

    abstract::Gefitinib (Iressa) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that offers treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), in particular in those who are harbouring EGFR mutations. In a large phase III trial (IPASS) in chemotherapy-naive Asian ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/10489100-000000000-00000

    authors: Sanford M,Scott LJ

    更新日期:2009-11-12 00:00:00

  • Certolizumab pegol: a review of its use in the management of rheumatoid arthritis.

    abstract::Certolizumab pegol (Cimzia(®)) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor (TNF)-α. The drug is indicated for subcutaneous use every 2 or 4 weeks (q2w or q4w) for the treatment of adults with mo...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0009-3

    authors: Deeks ED

    更新日期:2013-01-01 00:00:00